Kampala, Scidev.Net — As Uganda rolls out mandatory nationwide screening of newborns for sickle cell disease this month, a gene therapy celebrated in the United States and Europe remains financially out of reach for most patients in Africa. Ayoola Olajide, president of Ikorodu Sickle Cell Club in Nigeria and a person living with sickle cell…
Blu Label Unlimited Group co-CEO Brett Levy Blu Label Unlimited Group has declared its first interim dividend in eight years, signalling it is finally putting the long and costly Cell C chapter behind it. The group, formerly known as Blue Label Telecoms, declared an interim dividend of 43.56c/share for the six months to end-November 2025,…
BLU’s carrying value of Cell C has dropped. (Photograph by Nicola Mawson) JSE-listed Blu Label Unlimited is set to take a R5.2 billion hit on its stake in Cell C because the value of its investment at listing was lower than the value it was carrying on its books, resulting in an accounting loss. In…
Blu Label Unlimited Group will post a massive basic earnings loss for the six months to end-November 2025, driven almost entirely by a R5.2-billion accounting hit linked to its disposal of control in Cell C – but the company is keen to draw attention to what it says is a far more meaningful picture of…
Cell C CEO Jorge Mendes. (Photograph by Nicola Mawson) Cell C’s maiden interim results for the period to end-November saw it deliver on its pre-listing statement, leading to a share price lift. “Delivering our first interim results as a listed company is an important milestone for Cell C. Our focus has been on executing with…
Cell C has reported a R3.4-billion profit in its maiden results as a JSE-listed company, but the eye-catching number owes almost everything to a once-off balance sheet restructuring rather than underlying trading performance. The mobile operator, which listed on 27 November 2025 after a comprehensive debt-for-equity conversion, reported revenue of R5.7-billion for the six months…
Cell C CEO Jorges Mendes Cell C Holdings on Friday reported its financial results for the six months ended 30 November 2025, delivering its maiden results as a JSE-listed company and marking the transition to its next phase as a financially stronger business following the successful completion of its restructuring. Key highlights The results follow…
Cell C CEO Jorges Mendes Cell C’s leading market position as a platform for mobile virtual network operators (MVNOs) in South Africa is producing strong growth for the company. In its interim results for the six months to 30 November 2025 – the first since it listed on the JSE on 27 November – Cell…
Organ, Tissue and Cell Donation and Transplantation (OTCDT) is a medical procedure in which an organ, tissue or cell is removed from one body and placed in the body of a recipient to replace a damaged or missing structure. Transplantation involves organs, tissues and cells such as the kidneys, liver, lungs, pancreas, heart, small bowel,…
2025 marked a turning point for Cell C, says the company. 2025 marked a turning point for Cell C, with the operator focusing on stabilising its business, strengthening network partnerships and refining its strategy in a highly competitive mobile market. In an e-mail interview with ITWeb, Cell C CEO Jorge Mendes says: “We returned to…
